BY Richard Summerfield
Pharma giant Merck has agreed to acquire biotech company Prometheus Biosciences in a deal worth $10.8bn.
Under the terms of the deal, Merck will pay $200 per share for Prometheus, representing a 75.4 percent premium to Prometheus’ last closing price before the deal was announced.
Prometheus is a clinical-stage biotechnology company developing and commercialising novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases.
The acquisition of Prometheus will go some way toward replacing the huge revenue stream generated by Keytruda, which is likely to start fading early next decade as it loses its patents. Keytruda is used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer.
“At Merck, we are committed to delivering on our purpose to save and improve lives and continue to identify and secure opportunities where compelling science and value creation align,” said Robert M. Davis, chairman and chief executive of Merck. “The agreement with Prometheus will accelerate our growing presence in immunology where there remains substantial unmet patient need. This transaction adds diversity to our overall portfolio and is an important building block as we strengthen the sustainable innovation engine that will drive our growth well into the next decade.”
“Prometheus was established to revolutionize the treatment of immune-mediated diseases through the application of a powerful precision medicine approach,” said Mark McKenna, chairman and chief executive of Prometheus Biosciences. “This agreement with Merck, a leader in biopharmaceutical research and development, allows Prometheus to maximize the potential for PRA023, while continuing to apply our technology and expertise to fuel further discoveries to address the needs of patients with immune disorders.”
“By applying a portfolio of powerful analytic tools to a comprehensive collection of IBD samples, Prometheus identified important disease insights that have now yielded a promising late-stage candidate,” said Dean Y. Li, president of Merck Research Laboratories. “I look forward to working with the talented Prometheus team to establish a new paradigm of precision treatment for immune diseases.”
News: Merck to buy Prometheus Biosciences for about $11 billion